Tigercat Pharma Results From A Regional Partnership For CMEA's Velocity
This article was originally published in The Pink Sheet Daily
Executive Summary
The asset-focused operator of virtual biotechs teamed with Texas early-stage investment group Remeditex to back a new entity. Tigercat has filed an IND to investigate serlopitant for chronic itching.